Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

NCT01840579 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Non-small Cell Lung Cancer
Small Cell Lung Cancer

Interventions

BIOLOGICAL: Pembrolizumab 2 mg/kg
BIOLOGICAL: Pembrolizumab 10 mg/kg
BIOLOGICAL: Pembrolizumab 200 mg
DRUG: Cisplatin 75 mg/m^2
DRUG: Pemetrexed 500 mg/m^2
DRUG: Carboplatin AUC 5 mg/mL/min
DRUG: Carboplatin AUC 6 mg/mL/min
DRUG: Paclitaxel 200 mg/m^2
DRUG: Nab-paclitaxel 100 mg/m^2
BIOLOGICAL: Ipilimumab 1 mg/kg
DRUG: Etoposide 100 mg/m^2
DRUG: G-CSF (pegfilgrastim) 3.6 mg

Sponsor

Merck Sharp & Dohme LLC